Contraceptive Postmarketing Studies To Be Discussed By FDA Advisory Committee
This article was originally published in The Pink Sheet Daily
Agency seeks advice on how to get better information on safety and efficacy of hormonal contraceptives.
You may also be interested in...
PDUFA proposal expands scope of funding after FDA concludes that safety problems can occur well after a drug’s launch.
Document outlines the evaluation and development of appropriate PRO instruments to collect outcomes data that supports labeling claims.
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.